Harbour Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Harbour Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-60	Closed	-$1.89K	–	3851
2025 Q2	$1.89K	Hold	60	–	–	﹤0.01%	3148
2025 Q1	$1.97K	Hold	60	–	–	﹤0.01%	3087
2024 Q4	$2.17K	Hold	60	–	–	﹤0.01%	2995
2024 Q3	$1.87K	Hold	60	–	–	﹤0.01%	2941
2024 Q2	$1.6K	Hold	60	–	–	﹤0.01%	2871
2024 Q1	$2.05K	Hold	60	–	–	﹤0.01%	2777
2023 Q4	$1.74K	Hold	60	–	–	﹤0.01%	2718
2023 Q3	$1.65K	Hold	60	–	–	﹤0.01%	2595
2023 Q2	$1.8K	Sell	60 -30	-33%	-$1.05K	﹤0.01%	2572
2023 Q1	$3.26K	Hold	90	–	–	﹤0.01%	2425
2022 Q4	$3.21K	Sell	90 -32	-26%	-$1.11K	﹤0.01%	2378
2022 Q3	$4K	Hold	122	–	–	﹤0.01%	2264
2022 Q2	$4K	Buy	+122	New	+$3.49K	﹤0.01%	2264
2021 Q4	$4K	Hold	122	–	–	﹤0.01%	2265
2021 Q3	$3K	Sell	122 -343	-74%	-$9.21K	﹤0.01%	3226
2021 Q2	$14K	Buy	465 +12	+3%	+$368	﹤0.01%	2555
2021 Q1	$12K	Buy	+453	New	+$12.7K	﹤0.01%	2514

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harbour Investments's SUPN Position: Q3 2025 in Review

Harbour Investments sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 60 shares — an estimated $1.89K sold.

Harbour Investments first reported a position in SUPN in Q1 2021 and held it in 17 quarters. The position peaked at $14K in Q2 2021. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

Harbour Investments reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Harbour Investments sold 60 Supernus Pharmaceuticals shares in Q3 2025, an estimated $1.89K.
Harbour Investments first reported a position in Supernus Pharmaceuticals in Q1 2021 and held it in 17 quarters.
Harbour Investments's Supernus Pharmaceuticals position peaked at $14K in Q2 2021.
310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Harbour Investments's 13F filing for Q3 2025, filed 12 Nov 2025.